Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-39693 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-Phospho-DARPP-32 (Thr34) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinson's disease.
Cai HY, Fu XX, Jiang H, Han S
NPJ Parkinson's disease 2021 Oct 8;7(1):91
NPJ Parkinson's disease 2021 Oct 8;7(1):91
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-DARPP-32 pThr34 in extracts from NIH-3T3 cells using a Phospho-DARPP-32 pThr34 polyclonal antibody (Product # PA5-39693).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Phospho-DARPP-32 pThr34 in HepG2 cells using a Phospho-DARPP-32 pThr34 polyclonal antibody (Product # PA5-39693).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Phospho-DARPP-32 pThr34 in paraffin-embedded human brain tissue using a Phospho-DARPP-32 pThr34 polyclonal antibody (Product # PA5-39693).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 15 C16 in combination with Ang-1 treatment decreased the expression of phospho-DARPP-32, and increased the expression of pdyn and PPE. Western blot analysis showed no significant difference in the expression of DARPP-32 among the different groups ( a , b ). The expression of phospho-DARPP-32 in the vehicle-treated group was higher than that in normal controls ( c , d ). The combination of C16 and Ang-1 inhibited the upregulation of phospho-DARPP-32 in model animals. The downregulation of prodynorphin (pdyn, e , f ) and the upregulation of preproenkephalin (PPE, g , h ) in the model groups were remarkably reversed by treatment with C16, Ang-1, and C16 plus Ang-1. a p < 0.05 versus the normal control group; b p < 0.05 versus the vehicle group ( c ), p < 0.05 versus the C16-treated group ( d ), p < 0.05 versus the Ang-1-treated group. Darpp-32 protein: 34 kDa; pDarpp-32 protein: 34 kDa; Pdyn protein: 28 kDa; PPE protein: 30 kDa; beta-actin protein: 42 kDa; Abbreviations: DARPP, dopamine- and cAMP-regulated neuronal phosphoprotein; pdyn, prodynorphin; PPE, preproenkephalin; C16, peptide (KAFDITYVRLKF) that can selectively bind integrin alpha nu beta 3 ; Ang-1, angiopoietin-1.